a type I membrane protein of the immunoglobulin superfamily. Is a ligand for the leukocyte adhesion LFA-1 protein (Integrin alpha-L/beta-2) and a Rhinovirus receptor. Typically expressed on endothelial cells and cells of the immune system. ICAM1 binds to integrins of type CD11a / CD18, or CD11b / CD18. Its expression is activated by p53 in an NF-kappaB-independent manner. Induced by TNFalpha in a process that involves IKKbeta. Note: This description may include information from UniProtKB.
Protein type: Immunoglobulin superfamily; Cell adhesion; Membrane protein, integral
Cellular Component: extracellular space; integral to plasma membrane; plasma membrane; immunological synapse; external side of plasma membrane
Biological Process: adhesion to symbiont; positive regulation of nitric oxide biosynthetic process; T cell antigen processing and presentation; response to organic cyclic substance; activation of NF-kappaB transcription factor; positive regulation of cellular extravasation; regulation of cell shape; cellular response to nutrient levels; leukocyte adhesion; ovarian follicle development; T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell; membrane to membrane docking; response to sulfur dioxide; cell adhesion; regulation of leukocyte mediated cytotoxicity; regulation of cell adhesion; response to drug; virion attachment, binding of host cell surface receptor; negative regulation of calcium ion transport; regulation of immune response; cytokine and chemokine mediated signaling pathway; response to amphetamine; cell aging; response to amino acid stimulus; heterophilic cell adhesion; response to ethanol; response to copper ion; virus-host interaction; positive regulation of vasoconstriction; cell adhesion mediated by integrin; response to ionizing radiation; leukocyte migration
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.